TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · Real-Time Price · USD
25.71
+1.36 (5.59%)
At close: Oct 29, 2024, 4:00 PM
25.50
-0.21 (-0.82%)
After-hours: Oct 29, 2024, 7:25 PM EDT
TG Therapeutics Revenue
TG Therapeutics had revenue of $73.47M in the quarter ending June 30, 2024, with 357.05% growth. This brings the company's revenue in the last twelve months to $346.72M, up 1,341.56% year-over-year. In the year 2023, TG Therapeutics had annual revenue of $233.66M with 8,290.02% growth.
Revenue (ttm)
$346.72M
Revenue Growth
+1,341.56%
P/S Ratio
10.69
Revenue / Employee
$1,313,348
Employees
264
Market Cap
3.69B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 233.66M | 230.88M | 8,290.02% |
| Dec 31, 2022 | 2.79M | -3.90M | -58.36% |
| Dec 31, 2021 | 6.69M | 6.54M | 4,300.66% |
| Dec 31, 2020 | 152.00K | - | - |
| Dec 31, 2019 | 152.00K | - | - |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Perrigo Company | 4.43B |
| Envista Holdings | 2.53B |
| Amedisys | 2.29B |
| Apellis Pharmaceuticals | 628.79M |
| HUTCHMED (China) | 610.81M |
| Amicus Therapeutics | 455.66M |
| Axonics | 408.81M |
| PROCEPT BioRobotics | 176.58M |
TGTX News
- 5 weeks ago - TG Therapeutics: A Look At New Briumvi Data And Ocrevus Zunovo Approval - Seeking Alpha
- 5 weeks ago - New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis - GlobeNewsWire
- 5 weeks ago - New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment - GlobeNewsWire
- 7 weeks ago - TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2024 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting - GlobeNewsWire
- 2 months ago - TG Therapeutics Delivers A Beat-And-Raise Q2 And A $100 Million Buyback - Seeking Alpha
- 3 months ago - TG Therapeutics, Inc. (TGTX) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - HealthCare Royalty and Blue Owl Announce $250M Debt Financing with TG Therapeutics - Business Wire
- 3 months ago - TG Therapeutics to Host Conference Call on Second Quarter 2024 Financial Results and Business Update - GlobeNewsWire